greeksoup/ stock research
Stock research / United States / RMD · Surgical & Medical Instruments & Apparatus · NYSE

Resmed Inc. (RMD)

Resmed makes cloud-connected medical devices and the software around them, mostly for sleep and breathing disorders treated at home. It was formed in 1989 and commercialised continuous positive airway pressure treatment for obstructive sleep apnea, which was the first successful non-invasive treatment for the condition: a device delivers pressurised air, usually through a mask, to stop the upper airway collapsing during sleep. It employs approximately 11,370 people and sells in more than 140 countries through a mix of wholly owned subsidiaries and independent distributors. There are two segments, Sleep and Breathing Health and Residential Care Software.

Resmed Inc.

Resmed makes cloud-connected medical devices and the software around them, mostly for sleep and breathing disorders treated at home. It was formed in 1989 and commercialised continuous positive airway pressure treatment for obstructive sleep apnea, which was the first successful non-invasive treatment for the condition: a device delivers pressurised air, usually through a mask, to stop the upper airway collapsing during sleep. It employs approximately 11,370 people and sells in more than 140 countries through a mix of wholly owned subsidiaries and independent distributors. There are two segments, Sleep and Breathing Health and Residential Care Software.

Sleep and Breathing Health

The devices run from a night-time CPAP machine to non-invasive and invasive ventilators used for life support, and are used predominantly in the home and to a lesser extent in general and respiratory hospital wards. The range covers CPAP and bilevel systems, automatic positive airway pressure, adaptive servo-ventilation, high flow therapy devices, humidifiers and the accessories that go with them: masks, nasal cannula, headgear and tubing. The automatic devices, known as AutoSet, use patented technology to monitor breathing and in some countries can also be used in diagnosing and managing sleep apnea. AirMini, launched in fiscal 2017, is a small portable machine using the same therapy modes with waterless humidification. AirSense 11, launched in fiscal 2021, added a touch screen, algorithms for patients new to therapy and over-the-air updates. AirCurve 11 devices deliver different pressures for inhalation and exhalation. Devices were approximately 51% of net revenues in fiscal 2026, against 52% in each of the two preceding years.

Comfort is treated as a clinical problem, because patients historically found masks sore and struggled to fall asleep at the prescribed pressure. The answers named are more comfortable interfaces, delay timers that raise pressure gradually, bilevel devices, heated humidification and auto-titration that varies the average pressure through the night. myAir is the patient application, giving personalised coaching, daily therapy insights and a Smart Comfort feature that recommends settings such as ramp time and pressure relief so the patient does less trial and error. AirView is the clinician side, letting them remotely monitor patients on some ventilation and bilevel devices. The company reports an installed base of more than 35 million patients using cloud-connected devices on AirView and over 12 million patients registered on myAir.

Residential Care Software

Cloud-based software for providers in the residential care market: home medical equipment and home infusion providers, home health and hospice providers, skilled nursing facilities, private duty nursing organisations, senior living facilities and life plan communities. The platforms cover billing and business management, electronic medical records, revenue cycle management, operational analytics, patient engagement and workforce management, and are aimed at providers dealing with changing reimbursement rules, workforce constraints and demographic shifts. Brightree serves durable and home medical equipment providers in the United States, automating clinical workflows and billing and compliance. MEDIFOX DAN is the care management platform for residential care providers in Germany. MatrixCare covers senior living, skilled nursing, life plan communities, home health and hospice in the United States.

Two changes at the end of fiscal 2026

On 30 June 2026 the company agreed to sell the MatrixCare business for $490 million in cash, subject to closing adjustments. The sale covers MatrixCare and the related software sold under that brand, including Healthcare First, Citus and the home health and hospice products, and the filing describes it as portfolio optimisation to sharpen focus on sleep, breathing and connected home-based healthcare. It is expected to close in the first quarter of fiscal 2027.

In June 2026 the company acquired Noctrix Health, which holds a medical device classified by the Food and Drug Administration through the De Novo route that treats restless legs syndrome. Noctrix operates as a wholly owned subsidiary. Earlier, the 2025 acquisition of VirtuOx added a software-enabled independent diagnostic testing facility providing in-home and remote testing for sleep, respiratory, cardiac and other conditions across the United States.

From Resmed's annual report on Form 10-K for the year ended 30 June 2026. The filing

Compare with another name What $10,000 in Resmed became

Latest results

Latest quarterQ1 FY2027ended 30 September 2026 · 10-Q filed 30 October 2026
Revenue
$1.4 billion
+5.9% on the year · -3.3% on the quarter
Q2 FY2025Q1 FY2027
Net income
$418 million
+20.0% on the year · +9.1% on the quarter
Q2 FY2025Q1 FY2027
Diluted EPS
$2.92
+23.2% on the year · +10.6% on the quarter
Q2 FY2025Q1 FY2027

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q1 FY2027 results →the 10-Q on EDGAR ↗
Last full yearFY2026ended 30 June 2026 · 10-K filed 13 August 2026
Revenue
$5.7 billion
+9.9% on the year
FY2019FY2026
Net income
$1.5 billion
+8.8% on the year
FY2019FY2026
Diluted EPS
$10.43
+9.7% on the year
FY2019FY2026

this yearthe year beforeHover a bar for its figure.

The years before, in wordsResmed (RMD) reported revenue of $5.7 billion for fiscal 2026, the year ended 30 June 2026, up 9.9% on the year before. Net income was $1.5 billion and diluted earnings per share $10.43. Revenue was $5.1 billion in fiscal 2025, $4.7 billion in fiscal 2024, $4.2 billion in fiscal 2023 and $3.6 billion in fiscal 2022. Net income in the same years was $1.4 billion, $1.0 billion, $898 million and $779 million. Over the twelve months to 30 September 2026, Resmed reported revenue of $5.7 billion and net income of $1.6 billion. Revenue grew 12.1% a year, compounded, over the five years to fiscal 2026. Resmed declared $2.46 a share in dividends over the last four quarters and had 141 million shares outstanding at the latest filed count. At 30 September 2026 it carried $410 million of debt and $1.0 billion of cash. At the close of 6 November 2026 the market cap of Resmed was $33.1 billion, 21.4 times its earnings over the last twelve months.
Read the FY2026 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE26.8%
ROCE29.8%
Operating margin33.0%
Net margin27.8%
FCF margin28.1%
Interest covern/a
Debt to equity0.07x
Cash conversion1.11x
Share count, last 12 months-3.6%
Sales CAGR, 3 years10.2%
Profit CAGR, 3 years19.3%
EPS, TTM$10.98

At the close of 6 November 2026

Price$235.22
Market cap$33.1 billion
Stock P/E21.4x
Price to book5.6x
EV / EBITDA15.6x
Dividend yield1.0%
Market cap / sales5.8x
52-week high$275.96
52-week low$182.82
Price, 1 year-5.8%
Price CAGR, 3 years16.1%
Price CAGR, 5 years-2.0%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the total debt Resmed Inc. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
RMDgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026 †Q2 FY2026Q3 FY2026Q4 FY2026 *Q1 FY2027
Revenue8958649159501,0341,1171,1221,1021,1631,1971,2231,2251,2821,2921,3481,3361,4231,4311,4641,415
Cost of revenue391373392409454499505502516504508507531525528518544540602544
Gross profit504491523541580618617600647693716717751766820818879891861871
Gross margin56%57%57%57%56%55%55%54%56%58%58%59%59%59%61%61%62%62%59%62%
R&D62.566.864.363.269.976.478.175.773.977.180.979.581.483.986.489.591.094.3106103
SG&A185182195194212228240223222230242239242245265259278286296315
Operating income249234255276280301275289275375381387417426455447492500449453
Operating margin28%27%28%29%27%27%25%26%24%31%31%32%33%33%34%33%35%35%31%32%
Interest expense5.95.5n/an/an/an/an/an/an/an/an/an/an/an/an/a7.1n/an/an/a4.8
Pre-tax income237226238262274289277272259375358383418418458447496502474539
Tax rate15%21%18%20%18%20%17%19%20%20%18%19%18%13%17%22%21%21%19%22%
Net income202179195210225232230219209300292311345365380349393399383418
Net margin23%21%21%22%22%21%20%20%18%25%24%25%27%28%28%26%28%28%26%30%
Diluted EPS$1.37$1.22$1.32$1.43$1.53$1.58$1.56$1.49$1.42$2.04$1.98$2.11$2.34$2.48$2.58$2.37$2.68$2.74$2.64$2.92
Operating cash flow22011779.544.7129283237286273402440326309579539457340554455422
Capital expenditure30.448.428.629.127.428.834.430.023.421.224.917.820.620.830.643.028.533.751.148.7
Free cash flow18969.050.815.6101254203256249381415308288558508414311520404374
Buybacksn/an/an/an/an/a0.0n/a0.050.050.050.050.075.075.0100150175175200936
Dividends paid61.261.461.564.464.564.664.770.670.770.570.677.977.777.777.687.887.687.287.195.0
Shares outstanding146m146m146m146m147m147m147m147m147m147m147m147m147m147m146m146m146m145m144m141m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2009FY2010FY2011 †FY2012 †FY2013FY2014FY2015 †FY2016FY2017FY2018 †FY2019 †FY2020FY2021FY2022 †FY2023FY2024FY2025 †FY2026TTM
Revenue9211,0921,2431,3691,5141,5551,6791,8392,0672,3402,6072,9573,1973,5784,2234,6855,1465,6535,733
Cost of revenue3674375025485745656687728651,0051,1131,2391,3581,5541,8672,0302,0912,2022,231
Gross profit5546557418219419901,0111,0661,2021,3351,4941,7181,8392,0242,3562,6553,0553,4523,501
Gross margin60.1%60.0%59.6%60.0%62.1%63.7%60.2%58.0%58.1%57.0%57.3%58.1%57.5%56.6%55.8%56.7%59.4%61.1%61.1%
Research and development63.175.292.0110120118115119144155181202225254288308331378394
Selling, general and administrative2903293724034314504794885546006456776707388749179931,1201,175
Operating income1902402672943554054094294265425798109041,0001,1321,3201,6851,8871,893
Operating margin20.7%22.0%21.5%21.5%23.4%26.1%24.4%23.3%20.6%23.2%22.2%27.4%28.3%28.0%26.8%28.2%32.7%33.4%33.0%
Interest expensen/a2.71.84.86.46.15.811.228.228.436.240.424.0n/an/an/an/an/an/a
Pre-tax income2022613043323854314364404195215197338849601,1021,2651,6781,9192,012
Income tax55.270.576.777.178.085.883.087.276.5206114111409181204244277396419
Effective tax rate27.4%27.1%25.3%23.2%20.2%19.9%19.0%19.8%18.3%39.5%22.0%15.2%46.3%18.8%18.5%19.3%16.5%20.6%20.8%
Net income1461902272553073453533523423164056224757798981,0211,4011,5231,593
Net margin15.9%17.4%18.3%18.6%20.3%22.2%21.0%19.2%16.6%13.5%15.5%21.0%14.8%21.8%21.3%21.8%27.2%26.9%27.8%
Diluted EPS$0.95$1.23$1.44$1.71$2.10$2.39$2.47$2.49$2.40$2.19$2.80$4.27$3.24$5.30$6.09$6.92$9.51$10.43$10.98
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2018 to FY2026

FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026Share
of the parts, latest year
Sleep and Breathing Healthn/an/an/an/an/a3,7254,1014,5054,97888.0%
Residential Care Softwaren/an/an/an/an/a49858464167612.0%
Sleep and Respiratory Care2,1832,3312,6022,8233,177n/an/an/an/an/a
Software as a Service157276355374401n/an/an/an/an/a
Sleep and Breathing Health FY2023 to FY2026Residential Care Software FY2023 to FY2026Sleep and Respiratory Care FY2018 to FY2022Software as a Service FY2018 to FY2022
2,340FY20182,957FY20203,578FY20224,685FY20245,653FY2026

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Profit by segment FY2018 to FY2026

The operating profit each segment reports. Costs Resmed does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026Margin
FY2026
Sleep and Breathing Healthn/an/an/an/an/a1,4471,6811,9642,20444.3%
Residential Care Softwaren/an/an/an/an/a11615420521832.2%
Sleep and Respiratory Care6567669351,1701,280n/an/an/an/an/a
Software as a Service55.274.982.292.493.8n/an/an/an/an/a
Sleep and Breathing Health FY2023 to FY2026Sleep and Respiratory Care FY2018 to FY2022Residential Care Software FY2023 to FY2026Software as a Service FY2018 to FY2022
712FY20181,017FY20201,373FY20221,836FY20242,422FY2026

$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2026Share of salesShare of profit
Sleep and Breathing Health88%91%
Residential Care Software12%9%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by product or service FY2009 to FY2026

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026Share
of the parts, latest year
Sleep and Breathing Healthn/an/an/an/an/an/an/an/an/an/an/an/an/an/a3,7254,1014,5054,97888.0%
Residential Care Softwaren/an/an/an/an/an/an/an/an/an/an/an/an/an/a49858464167612.0%
Devicesn/an/an/an/an/an/a9761,0641,161n/an/an/an/an/an/an/an/an/an/a
Flow Generators532634699737824847n/an/an/an/an/an/an/an/an/an/an/an/an/a
Masks And Other Accessories389459544632691708703746768n/an/an/an/an/an/an/an/an/an/a
Sleep and Respiratory Caren/an/an/an/an/an/an/an/an/a2,1832,3312,6022,8233,177n/an/an/an/an/a
Software as a Servicen/an/an/an/an/an/an/an/an/a157276355374401n/an/an/an/an/a
Not assigned to a part in the filingn/an/an/an/an/an/an/a28.9138n/an/an/an/an/an/an/an/an/an/a
Sleep and Breathing Health FY2023 to FY2026Residential Care Software FY2023 to FY2026Sleep and Respiratory Care FY2018 to FY2022Software as a Service FY2018 to FY2022Masks And Other Accessories FY2009 to FY2017Devices FY2015 to FY2017Flow Generators FY2009 to FY2014
1,243FY20111,555FY20141,929FY20172,957FY20204,223FY20235,653FY2026

$ million; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Not assigned to a part in the filing is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Revenue by region FY2012 to FY2026

FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026Share
of the parts, latest year
United Statesn/an/an/a9041,0561,2291,3451,5891,8291,9632,2492,7202,9803,2863,56263.0%
Rest of the World2632933495907828389951,0181,1281,2341,3291,5031,7051,8612,09137.0%
Australia35.735.5n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
France139139152n/an/an/an/an/an/an/an/an/an/an/an/an/a
Germany181195215184n/an/an/an/an/an/an/an/an/an/an/an/a
North And Latin America749852839n/an/an/an/an/an/an/an/an/an/an/an/an/a
United States FY2015 to FY2026Rest of the WorldGermany FY2012 to FY2015North And Latin America FY2012 to FY2014France FY2012 to FY2014Australia FY2012 to FY2013
1,369FY20121,555FY20141,839FY20162,340FY20182,957FY20203,578FY20224,685FY20245,653FY2026

$ million; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2009FY2010FY2011 †FY2012 †FY2013FY2014FY2015 †FY2016FY2017FY2018 †FY2019 †FY2020FY2021FY2022 †FY2023FY2024FY2025 †FY2026TTM
Operating cash flow2391882833834033913835484145054598027373516931,4011,7521,8061,771
Capital expenditure11056.966.647.163.672.762.558.562.262.668.795.310313512099.589.9156162
Free cash flow1291312173363393193214893524423907076342165741,3021,6621,6501,609
Free cash flow margin14.0%12.0%17.4%24.6%22.4%20.5%19.1%26.6%17.0%18.9%15.0%23.9%19.8%6.0%13.6%27.8%32.3%29.2%28.1%
Cash from investing-109-58.3-76.5-102-78.0n/an/a-1,126-81.9-102-1,076-180-158-230-1,160-270-200-545-101
Cash from financing1.9-61.1-79.3-177-154n/an/a613-263-1,027581-317-765-128423-1,119-606-1,007-2,055
Depreciation and amortisation54.061.670.685.978.373.573.186.8112120151155157160165177198201195
Share-based compensation25.529.730.830.638.243.547.946.445.948.452.157.663.965.371.180.291.7104113
Buybacks68.6131163393186202160102n/a53.822.8n/an/a0.00.01503007001,486
Dividends paidn/an/an/an/a97.2142157168186199212225227245258282311350357
Dividend per sharen/an/an/an/a$0.68$1.00$1.12$1.20$1.32$1.40$1.48$1.56$1.56$1.68$1.76$1.92$2.12$2.40n/a
Diluted shares, weighted154m155m157m149m146m144m143m142m142m144m144m146m146m147m147m148m147m146m143m
Shares outstanding at period endn/a151m152m142m142m140m140m141m142m143m144m145m146m146m147m147m146m144m141m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2009FY2010FY2011 †FY2012 †FY2013FY2014FY2015 †FY2016FY2017FY2018 †FY2019 †FY2020FY2021FY2022 †FY2023FY2024FY2025 †FY2026TTM
Funded by
Shareholders' equity1,1151,2881,7311,6081,6111,7581,5871,6951,9602,0592,0722,4972,8863,3614,1304,8645,9686,5855,948
Debtn/a1221002513013013011,1751,0792811,2711,1766557751,441707668659410
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/a102115120117141153137169
Other liabilitiesn/a2172382792993022963894307237658121,0728391,0641,1601,3851,5841,685
Total liabilities and equityn/a1,6262,0692,1382,2112,3612,1843,2593,4683,0644,1084,5874,7285,0966,7526,8728,1748,9668,212
Owned
Fixed assetsn/a387462434411434388384394387387417463498538548551582602
Goodwilln/a1992352562752892641,0591,0651,0691,8561,8901,9281,9362,7702,8423,0472,9102,908
Intangible assetsn/a30.947.954.849.645.247.1300262215522448393346552486465453443
Securities held for sale or to maturityn/an/a0.0n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Cash and equivalents4164897358108769067177318221891474632952742282381,2091,4691,011
Receivablesn/a2272742833183603633824514845284756145767058379391,036972
Inventoryn/a1862011741461652472242682693504174577449988229289461,021
Other assetsn/a1081131251351611581782074523174775787229601,0991,0351,5711,255
Total assetsn/a1,6262,0692,1382,2112,3612,1843,2593,4683,0644,1084,5874,7285,0966,7526,8728,1748,9668,212
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded11.9%12.1%10.2%9.0%
Profit growth, compounded15.8%26.3%19.3%10.8%
Return on equity, average20.6%22.5%22.5%23.1%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Resmed's revenue in fiscal 2026?

Resmed (RMD) reported revenue of $5.7 billion for fiscal 2026, the year ended 30 June 2026, up 9.9% on the year before.

How much did Resmed earn in fiscal 2026?

Net income was $1.5 billion for fiscal 2026, and diluted earnings per share $10.43.

What is Resmed's P/E ratio?

At the close of 6 November 2026, Resmed traded at 21.4 times its earnings over the twelve months to 30 September 2026.

What is Resmed's market cap?

The market cap of Resmed was $33.1 billion at the close of 6 November 2026.

Does Resmed pay a dividend?

Yes. Resmed declared $2.46 a share in dividends over the four quarters to 30 September 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
70 companies share its SEC industry code (Surgical & Medical Instruments & Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on RMD

Dividends$2.46 a share over the four quarters to 30 September 2026, a 1.05% yield
Filings19 in twelve months: 9 current reports (8-K), about 5 results of operations; 5 other events; 3 officer or director change; 2 regulation FD disclosure; 1 change of auditor
Planned insider sales31 Form 144 notices in twelve months, $21.3 million; latest 23 October 2026
Options tapeput/call 3.66 by open interest at the 6 November 2026 close; the straddle prices a 5.5% move to 20 November 2026
13F holders894 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading31 sales and 0 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest11.9 million shares short, 12.33 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202630 October 2026EDGAR
10-K30 June 202613 August 2026EDGAR
10-Q31 March 20261 May 2026EDGAR
10-Q31 December 202530 January 2026EDGAR
10-Q30 September 202531 October 2025EDGAR
10-K30 June 20258 August 2025EDGAR
10-Q31 March 202524 April 2025EDGAR
10-Q31 December 202431 January 2025EDGAR
10-Q30 September 202425 October 2024EDGAR
10-K30 June 20249 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.